Matches 1 - 50 out of 176 1 2 3 4 >


Match Document Document Title
US20120114767 System and Method for Diagnosis and Treatment of Neuropsychiatric Disorders  
An assay for a GCH1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological...
US20140047569 Methods of Treating Disorders Associated with Protein Aggregation  
The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein...
US20130024953 Methods of Treating Disorders Associated with Protein Aggregation  
The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein...
US20110150775 GENOMIC APPROACHES TO FETAL TREATMENT AND DIAGNOSIS  
The present invention provides systems for developing and/or testing therapies for prenatal diseases and conditions including Down Syndrome. The present invention also provides diagnostic methods...
US20130224289 GASTRIC RETAINED GABAPENTIN DOSAGE FORM  
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
US20120282307 GASTRIC RETAINED GABAPENTIN DOSAGE FORM  
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
US20120064129 GASTRIC RETAINED GABAPENTIN DOSAGE FORM  
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
US20110118189 NOVEL FORMULATIONS FOR TREATMENT OF MIGRAINE  
Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting,...
US20150119383 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20130245004 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20130143867 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20120128735 METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE  
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.
US20120064168 METHODS OF TREATMENT USING A GASTRIC RETAINED GABEPENTIN DOSAGE  
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.
US20130090329 Methods and Compositions for the Treatment of Psychotic Disorders Through the Identification of the Olanzapine Poor Response Predictor Genetic Signature  
Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a OPRP genetic...
US20110281855 NOVEL AND POTENT TAPENTADOL DOSAGE FORMS  
The present invention provides a dosage form comprising at least one form of tapentadol, with or without a second analgesic, and at least one opioid antagonist, wherein tapentadol is present in an...
US20120277211 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE SULT4A1-1 HAPLOTYPE  
Methods and compositions that relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1...
US20110105469 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE SULT4A1-1 HAPLOTYPE  
Methods and compositions that relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1...
US20110105468 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE SULT4A1-1 HAPLOTYPE  
Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1...
US20110105467 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE SULT4A1-1 HAPLOTYPE  
Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1...
US20140234443 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF  
Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and...
US20150031677 TRIOXANE THIOACETAL MONOMERS AND DIMERS AND METHODS OF USE THEREOF  
Monomeric and dimeric trioxane thioacetals and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic...
US20130035304 SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS  
This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of...
US20150157558 METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE FORM  
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.
US20140350000 Genetic Markers for Optimizing Treatment for Schizophrenia  
This document provides methods and materials related to genetic markers for predicting response to a treatment for schizophrenia (SZ). For example, methods for using such genetic markers to select...
US20100310681 Modulation of KCNQ Potassium Channel Activity for Treatment of Psychiatric Disorders and the Symptoms Thereof  
Disclosed herein are compositions and methods for treating a psychiatric disorder or symptoms thereof in a patient. The compositions comprise a compound that modulates KCNQ (Kv7) potassium channel...
US20110319382 COMPOSITIONS COMPRISING A CALCIUM CHANNEL BLOCKER OR A CALMODULIN BLOCKER FOR USE IN THE REMOVAL OF HYPERPLASTIC SKIN LESIONS  
A composition, use of and a method of removing a hyperplastic skin lesion on a mammal comprising administering to the lesion or locus thereof a therapeutically effective amount of a composition...
US20060063753 Use of nefopam for the treatment of nausea or emesis  
The invention relates to the use of nefopam for the manufacture of a medicament for the treatment of nausea, dizziness, blurred vision and emesis.
US20100190705 Suppression of glial fibrillary acidic protein  
Provided herein are methods of decreasing glial fibrillary acidic protein (GFAP) levels in a cell. Such methods include administering an effective amount of a GFAP lowering compound to the cell....
US20120245145 METHOD AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF BROAD SPECTRUM VIRUS AILMENTS COMPRISING A CALCIUM CHANNEL BLOCKER OR A CALMODULIN BLOCKER  
In the broadest aspect, the invention provides a composition for and a method of prophylactic and/or therapeutic treatment of a animal/mammal for any viral disease, mixed bacterial and viral...
US20130189333 ORAL PRODUCT  
An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and an...
US20140024638 TREATMENT OF COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA  
The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3- yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof, pharmaceutical...
US20140288054 GENETIC MARKERS OF MENTAL ILLNESS  
This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof.
US20150098978 DISSOLVABLE-CHEWABLE TABLET  
A tablet that includes a solid solution of soluble fiber and one or more sugar alcohols, the solid solution having a glass transition temperature of less than 40° C., and one or more additives...
US20140255499 Method of Forming Fine Particles of a Drug Substance  
A method of forming fine particles of a drug substance using a piston-gap high pressure homogeniser.
US20130184268 2-(R2-THIO)-10-[3-(4-R1-PIPERAZIN-1-YL) PROPYL]-10H-PHENOTHIAZINE FOR TREATING A BETA-AMYLOIDOPATHY OR AN ALPHA-SYNUCLEOPATHY, AND METHOD FOR THE DIAGNOSIS OR PREDIAGNOSIS THEREOF  
The invention relates to 2-(R2-thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothia zine according to general formula I, for treating a β-amyloidopathy or an α-synucleinopathy accompanied by a...
US20100305103 GENES DIFFERENTIALLY EXPRESSED IN BIPOLAR DISORDER AND/OR SCHIZOPHRENIA  
This invention provides molecular markers that are prognostic and/or diagnostic for a psychiatric disorder. In particular, genes are identified whose expression is altered in schizophrenia and/or...
US20140294994 PHARMACEUTICAL COMPOSITION FOR ELIMINATION OF CANCER STEM CELLS  
The preset invention relates to use of antipsychotic phenothiazine derivative for eliminating cancer stem cells (CSCs) and/or preventing a cancer. The invention also provides a pharmaceutical...
US20100189698 TREATMENT OR PROPHYLAXIS OF A NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS VIA OCULAR ADMINISTRATION  
A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need...
US20080242657 Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists  
Histamine H3 inverse agonists or histamine H3 antagonists are useful, alone or in combination with a neuroleptic agent, for treating or preventing movement disorders, including tremor, such as...
US20110177999 Therapeutic Combinations Useful in Treating CFTR Related Diseases  
The present invention relates to therapeutic combinations and kits useful in treating CFTR-related diseases, such as cystic fibrosis.
US20090029967 ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS  
There is disclosed a method for the treatment or prevention of Extra Pyramidal syndrome (EPS), dystonia, restless leg syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the...
US20090148543 Method for protecting humans against superficial vasodilator flush syndrome,  
Methods for protection of a human from SVFS comprise the administration of a flavonoid compound of the basic structures 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides...
US20140364383 METHODS AND COMPOSITIONS FOR APPLYING PHARMACOLOGIC AGENTS TO THE EAR  
Methods and materials useful for applying pharmacologic agents to the ear are described. The methods involve delivering a composition that contains at least one viscogenic agent and at least one...
US20060233843 Treatment of psychosis with a muscarinic m1 receptor ectopic activator  
A muscarinic M1 receptor ectopic activator, such as a muscarinic M1 receptor allosteric potentiator or a muscarinic M1 receptor ectopic agonist is useful, alone or in combination with other...
US20120172292 METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE  
This invention discloses a method for enhancing the efficacy of antimicrobial, anti-protozoa and anti-cancer treatments by co-administering an inhibitor of endogenous NO production and/or NO...
US20120108545 Trioxane Monomers and Dimers  
Monomeric and dimeric trioxane fluoroaryl amides, 5-carbon-linked, C-10 non-acetal trioxane dimer esters; trioxane silylamides; and trioxane dimer orthoesters and methods of their use for treating...
US20050176650 Stable parenteral formulation of levomepromazine and a method for stabilizing said formulation  
The present invention relates to stabilized formulations for parenteral administration comprising a therapeutically effective amount of levomepromazine or a pharmaceutically acceptable salt...
US20130289023 METHOD FOR TREATING BRAIN TUMOR  
The preset invention relates to a new method for treating brain tumor with an antipsychotic phenothiazine derivative as a brain tumor cell inhibitor or a brain tumor stem cell inhibitor. In...
US20140038949 DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE  
The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The...
US20110223221 STABILIZATION PROCESSES OF CATION RADICALS OF PHENOTHIAZINIC COMPOUNDS, COSMECEUTICAL FORMULATIONS AND METHODS FOR SKIN DISEASES AND DISTURBANCES PREVENTION  
The present invention relates to processes of stabilization of cation radicals from one or more phenothiazinic compounds or derivatived compounds thereof. Another embodiment of the present...

Matches 1 - 50 out of 176 1 2 3 4 >